Postpartum depression drugs are used to treat mood disorders in women after childbirth. These drugs help reduce symptoms of depression such as crying spells, anxiety, insomnia, fatigue, changes in appetite, difficulty concentrating, feelings of sadness, worthlessness and guilt. With rising awareness about postpartum depression and its treatment through effective prescription drugs, the demand for postpartum depression drugs is growing substantially. The global postpartum depression drug market is estimated to be valued at US$ 7.67 Bn in 2024 and is expected to exhibit a CAGR of 26.% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The increasing prevalence of postpartum depression presents a major market opportunity. According to the World Health Organization (WHO), around 13% of women globally suffer from postpartum depression. Further, a study published in the Journal of Women's Health found that nearly 1 in 7 women experience symptoms of postpartum depression. The condition affects nearly half a million women annually in the U.S. alone. With growing diagnosis rates, an increasing number of women are seeking effective prescription medications to alleviate their symptoms. This rising disease prevalence is expected to drive significant demand for postpartum depression drugs over the forecast period.
Porter’s Analysis
Threat of new entrants: The postpartum depression drug market has high entry barriers due to the required research and development as well as stringent regulatory approvals.
Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of alternative treatment options. However, patented drugs ensure their demand.
Bargaining power of suppliers: Suppliers have moderate-to-high bargaining power owing to the specialized ingredients and materials required for manufacturing postpartum depression drugs.
Threat of new substitutes: Substitutes have low threat as alternative treatment options have significant limitations compared to prescribed drugs.
Competitive rivalry: Intense due to the presence of major established players.
SWOT Analysis
Strength: Large patient pool and high unmet needs. Increasing awareness.
Weakness: Low diagnosis rates. Side effects of few drugs.
Opportunity: Emerging economies with growing healthcare spends. New drug delivery methods.
Threats: Patent expiries. Stringent regulations.
Key Takeaways
The global Postpartum Depression Drug Market is expected to witness high growth at a CAGR of 26% during the forecast period of 2024 to 2031. The market size is projected to reach US$ 7.67 Bn by 2024.
Regional analysis shows that North America currently dominates the market with the highest diagnosed postpartum depression cases and increasing funding for relevant R&D activities. However, Asia Pacific is likely to emerge as the fastest-growing region owing to growing awareness, improving access to healthcare facilities, and rising healthcare expenditures.
Key players operating in the postpartum depression drug market are Salesforce.com Inc., Appian Corporation, Microsoft Corporation, Magic Software Enterprises Ltd, Pegasystems Inc., Oracle Corporation, ZOHO Corporation, Mendix Inc. (Siemens AG), AgilePoint Inc., QuickBase Inc., Clear Software LLC (Microsoft Corporation), ServiceNow Inc., Skuid Inc., Outsystems Inc., Temenos AG.
For more insights, read- https://www.insightprobing.com/postpartum-depression-drug-market-trends-size-and-share-analysis/
For more details on the report, Read- https://dailynewsmotion.weebly.com/report-blog/plant-based-meat-market-is-estimated-to-witness-high-growth-owing-to-opportunity
